**High-Level Overview (2–3 sentences)**  
The talk presents an update on GTX‑102, an investigational antisense oligonucleotide (ASO) therapy for Angelman syndrome, focusing on what has been learned from early trials and how community input has shaped the program. Dr. Kim Goodspeed explains safety and efficacy findings from the Phase 1/2 study, introduces the multi‑domain responder index (MDRI) as a way to measure meaningful change across multiple symptoms, and outlines the design of the ongoing Phase 3 (ASPIRE) and new Phase 2 (AURORA) trials, including expansion to all genotypes and a broader age range.

---

## Speaker Introduction

- **Name:** Dr. Kim Goodspeed, MD  
- **Training and background:** Child neurologist (pediatric neurology), with clinical and research expertise in neurodevelopmental disorders.  
- **Current role:** Clinical Development Lead for the GTX‑102 program at **Ultragenyx Pharmaceutical**.  
- **Affiliation:** Ultragenyx is a biotechnology company focused exclusively on rare and ultra‑rare diseases, founded in 2010 by Dr. Emil (Amal) Kakkis. The company has ~1300 employees worldwide and develops therapies for conditions with few or no existing treatments.  
- **Role in this program:** Oversees clinical trial design, execution, and interpretation for GTX‑102 in Angelman syndrome, and serves as a key liaison with the Angelman community, investigators, and regulators.

---

## Main Sections / Topics (in order)

1. Ultragenyx and GTX‑102: What the drug is and current safety experience  
2. Lesson 1 – “Measure what matters”: Choosing outcome measures and the MDRI  
3. Lesson 2 – Patient‑focused study design and the ASPIRE Phase 3 trial  
4. Lesson 3 – Inclusion of all genotypes and ages: The AURORA Phase 2 trial  
5. Overall trial program structure and long‑term extension  
6. How families can engage and key takeaways

---

### 1. Ultragenyx and GTX‑102: What the drug is and current safety experience

**Key takeaways and explanations (≤5 sentences)**  
- **Ultragenyx** is a rare‑disease–only company; its founder, Dr. Emil Kakkis, created it to solve the specific challenges of drug development in very small patient populations.  
- **GTX‑102** is an **antisense oligonucleotide (ASO)** designed for Angelman syndrome: it binds to the *UBE3A* antisense transcript that normally silences the paternal copy of the gene in neurons, leading to degradation of that antisense RNA and allowing the paternal allele to express UBE3A protein (“using the backup copy from dad”).  
- In the Phase 1/2 trial, GTX‑102 has shown **improvements across several core Angelman symptoms** (e.g., cognition, communication, behavior, sleep) and an overall **favorable safety profile**.  
- A key monitored safety issue is **radiculopathy** (an “adverse event of special interest”): some children experienced temporary sensory or motor changes affecting walking, but all recovered fully, were able to restart treatment, and did not have recurrence when re‑dosed.  
- The team now understands how to **monitor, identify, and manage** this event, and emphasizes that safety oversight is central as they move into larger and broader trials.

---

### 2. Lesson 1 – “Measure what matters”: Choosing outcome measures and the MDRI

**Key takeaways and explanations (≤5 sentences)**  
- The first major lesson from the community is to **“measure what matters”**—to turn the real‑world challenges families describe (sleep, behavior, communication, seizures, etc.) into **quantifiable clinical outcome measures**.  
- Ultragenyx uses data from **natural history studies**, **disease concept studies**, and their own **baseline trial data** to confirm that standard tools (e.g., Bayley scales, Vineland, behavior and sleep questionnaires) truly capture the symptoms families say are most important.  
- They also conduct **qualitative caregiver interviews** at baseline and during the trial to add context—e.g., what “behavior problems” actually look like at home—and then link these narratives to the numerical scores.  
- Because a single primary endpoint can miss important benefits and exclude patients who might improve in other domains, they developed a **Multi‑Domain Responder Index (MDRI)** to assess change across multiple independent symptom domains at once.  
- The MDRI is a **statistical framework** that assigns each domain (e.g., sleep, behavior, communication, motor function, seizures) a specific outcome measure and a **clinically meaningful threshold** for improvement or worsening, then summarizes each participant’s net response across all domains.

---

### 3. The Multi‑Domain Responder Index (MDRI): How it works and what it shows

**Key takeaways and explanations (≤5 sentences)**  
- For each domain, the team defines a **“meaningful score difference” (MSD)**—a threshold beyond which change is considered clinically important (formerly called “minimal important difference”); crossing this threshold in the direction of improvement yields a **+1 (green box)**, in the direction of worsening a **–1 (pink box)**, and changes within the gray zone are **0 (white box)**.  
- Each participant’s **net response score** is the sum of these domain scores (e.g., +5 if all five domains improve; +3 if three improve and two are unchanged; 0 if improvements and worsenings balance out).  
- This differs from a **composite endpoint**, which typically combines multiple measures of a *single* symptom; the MDRI instead combines **different symptoms**, each measured independently, into one analytic view.  
- Applying the MDRI to Phase 1/2 cohorts A and B at ~1 year (day 338), **22 of 28 children (79%)** had a **positive net response** (at least one domain with clinically meaningful improvement), while individual children showed different patterns of which domains improved, stayed stable, or worsened.  
- The MDRI thus provides a **“bird’s‑eye view”** of how a complex, multi‑symptom disorder like Angelman responds to treatment, capturing heterogeneity in individual responses while still allowing rigorous statistical testing.

---

### 4. Lesson 2 – Patient‑focused study design and the ASPIRE Phase 3 trial

**Key takeaways and explanations (≤5 sentences)**  
- Ultragenyx emphasizes **patient‑focused drug development**, incorporating both formal and informal feedback from families and advocacy groups (including FAST) into trial design.  
- In rare diseases, traditional **placebo‑controlled** designs (where a fake drug is given) can be ethically and practically challenging, so they explored alternatives and listened to European families’ feedback to regulators (EMA) that **sham control** was preferred.  
- A **sham control** means the procedure (e.g., lumbar puncture) is performed to mimic drug administration, but **no active or placebo drug is injected**; this preserves blinding while avoiding exposure to an inert substance.  
- The **ASPIRE Phase 3 trial** is a global, double‑blind, sham‑controlled study in **129 children aged 4–17 with deletion genotypes**, using similar outcome measures as Phase 1/2; participants are randomized 1:1 to receive either GTX‑102 or sham procedures for the first year.  
- In year 2, the trial becomes **open‑label**, and all participants—including those initially in the sham arm—receive GTX‑102, following the same dosing regimen, while some lumbar punctures are used to collect spinal fluid for safety and biomarker analyses.

---

### 5. Lesson 3 – Inclusion of all genotypes and ages: The AURORA Phase 2 trial

**Key takeaways and explanations (≤5 sentences)**  
- The community insisted—and Ultragenyx agreed—that a therapy designed to restore UBE3A should ultimately be evaluated in **all Angelman genotypes and across ages**, not just deletion genotypes in children.  
- Earlier Phase 1/2 and Phase 3 ASPIRE studies focused on **4–17‑year‑olds with deletion genotypes** to establish initial safety and efficacy; the new **AURORA Phase 2 trial** expands to younger children, adults, and non‑deletion genotypes.  
- AURORA is a **global, Phase 2 “basket” study** (one protocol with multiple subgroups) enrolling about **60 children and adults**, with outcome measures tailored to age and genotype (e.g., behavior scales appropriate for adults vs. young children).  
- The groups are:  
  - **Group A:** Deletion genotype, ages 1–3 (younger children)  
  - **Group B:** UPD/ICD genotypes, ages 4–17  
  - **Group C:** Adults, any genotype  
  - **Group D:** Mutation genotype, ages 4–17  
- Groups A, B, and C receive **one year of open‑label treatment**; Group D includes a **2:1 randomization** where two children start treatment immediately and one has a **6‑month no‑treatment control period** before starting GTX‑102, to better understand natural variability and pre‑treatment trajectories in this more heterogeneous group.

---

### 6. Overall trial program structure and long‑term extension

**Key takeaways and explanations (≤5 sentences)**  
- The GTX‑102 program follows the typical rare‑disease pathway: **Phase 1/2** for initial safety and efficacy, **Phase 3 (ASPIRE)** as the pivotal, controlled trial to assess benefit–risk, and **Phase 2 (AURORA)** to extend evaluation to additional populations.  
- The original **Phase 1/2 trial** in 4–17‑year‑olds with deletion genotypes is complete for enrollment, and participants are now in a **long‑term extension (LTE)** study to monitor sustained safety and long‑term efficacy on maintenance dosing.  
- **ASPIRE** completed enrollment in mid‑2024; data are now “cooking” (being collected and not yet analyzed) until the prespecified timepoints are reached.  
- **AURORA** opened for enrollment in October and is actively recruiting; all participants from parent studies (ASPIRE or AURORA) can transition into the **LTE**, ensuring continued access to GTX‑102 if they and their families choose.  
- Detailed protocol information for all studies is available on **ClinicalTrials.gov (ct.gov)**, though the site can be dense; Ultragenyx encourages families to familiarize themselves with it.

---

### 7. How families can engage and key takeaways

**Key takeaways and actionable points (≤5 sentences)**  
- Families interested in GTX‑102 trials can contact the **Ultragenyx clinical team** (via email or at conference booths) to be connected with nearby trial sites and to discuss eligibility and logistics before site visits.  
- Ultragenyx encourages families to **talk with their own physicians**, other families, and study teams to understand what participation in a clinical trial entails and to decide what is right for them.  
- The **Phase 1/2 data** show a **promising benefit–risk profile**, justifying continued development and larger controlled studies.  
- The **MDRI** is highlighted as a powerful way to capture **meaningful improvements across multiple domains** in a complex condition like Angelman syndrome, rather than relying on a single primary endpoint.  
- AURORA’s launch, including **all ages and all genotypes**, fulfills a promise made to the community that the program would not remain limited to a narrow subset of Angelman patients.